Copay Assistance Programs Threatened By Medicaid Best Price Rule – PhRMA Lawsuit
The regulatory provisions being challenged are part of a Trump-era “midnight rule” that could be changed by the Biden Administration before implementation, but PhRMA is not taking any chances about the future of copay assistance programs.
You may also be interested in...
CMS final rule narrows definition of new formulations potentially subject to much higher Medicaid rebates and delays effective date of provisions targeting health plan copay accumulator programs.
Annual large US employer health benefits survey also evaluates plans for managing the cost of cell and gene therapies in the coming years, anticipating growing use of outcomes-based contracts, but very limited uptake of payment-over-time models.
Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.